Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | RAD52 | P43351 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5507449 | 0.98 | NAAA (0.53) | NAAAHCAR2EPHX1ATMTSHR | |
| SCHEMBL5514096 | 0.98 | NAAA (0.53) | NAAAHCAR2EPHX1ATMTSHR | |
| SCHEMBL5510321 | 0.98 | NAAA (0.53) | NAAAHCAR2EPHX1ATMTSHR | |
| SCHEMBL5506856 | 0.98 | NAAA (0.53) | NAAAHCAR2EPHX1ATMTSHR | |
| SCHEMBL5517476 | 0.98 | NAAA (0.53) | NAAAHCAR2EPHX1ATMTSHR | |
| SCHEMBL5512249 | 0.98 | NAAA (0.53) | NAAAHCAR2EPHX1ATMTSHR | |
| SCHEMBL5512033 | 0.98 | NAAA (0.53) | NAAAHCAR2EPHX1ATMTSHR | |
| SCHEMBL450585 | 0.98 | NAAA (0.53) | NAAAHCAR2EPHX1ATMTSHR | |
| SCHEMBL444270 | 0.94 | ATM (0.54) | NAAAHCAR2EPHX1ATMTSHR | |
| SCHEMBL446279 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 277 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004046153-A1 | PRODRUG ESTERS OF CEFTRIAXONE | RANBAXY LABORATORIES LIMITED (IN) | 2004-06-03 | — | — | WO | claimed |
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2024-04-25 | — | — | US | disclosed |
| EP-4025253-B1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR SA (ES) | 2024-03-20 | — | — | EP | disclosed |
| CN-114615999-B | Drug antibody conjugates | 法马马有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-20230218774-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2023-07-13 | — | — | US | disclosed |
| EP-4138923-A1 | DRUG ANTIBODY CONJUGATES | Pharma Mar, S.A. (ES) | 2023-03-01 | — | — | EP | disclosed |
| US-20230012681-A1 | ANTIBODY DRUG CONJUGATES COMPRISING ECTEINASCIDIN DERIVATIVES | PHARMA MAR, S.A. (ES) | 2023-01-19 | — | — | US | disclosed |
| EP-3870234-B1 | ANTIBODY DRUG CONJUGATES COMPRISING ECTEINASCIDIN DERIVATIVES | PHARMA MAR SA (ES) | 2022-12-21 | — | — | EP | disclosed |
| EP-4025253-A1 | DRUG ANTIBODY CONJUGATES | Pharma Mar S.A. (ES) | 2022-07-13 | — | — | EP | disclosed |
| CN-114615999-A | Drug antibody conjugates | 法马马有限公司 | 2022-06-10 | — | — | CN | disclosed |
| EP-0272583-A2 | 5-Substituted amino-4-hydroxy-pentenoic acid derivatives and their use | Banyu Pharmaceutical Co., Ltd. (JP) | 1988-06-29 | — | — | EP | disclosed |
| EP-0264106-A2 | 5-Substituted amino-4-hydroxy-pentanoic acid derivatives and their use | Banyu Pharmaceutical Co., Ltd. (JP) | 1988-04-20 | — | — | EP | disclosed |
| EP-0108942-B1 | CEPHALOSPORIN DERIVATIVES, METHODS OF PRODUCTION THEREOF AND PROPHYLACTIC AND THERAPEUTIC AGENTS FOR BACTERIAL INFECTION | KYOTO PHARMA IND (JP) | 1988-03-02 | — | — | EP | disclosed |
| EP-0233946-A1 | CHROMOGLYCIC ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND MEDICINAL COMPOSITION | Kyoto Pharmaceutical Industries, Ltd. (JP) | 1987-09-02 | — | — | EP | disclosed |
| US-4605651-A | BACTERICIDES | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1986-08-12 | — | — | US | disclosed |
| EP-0072710-B1 | CARBAPENEM DERIVATIVES, THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | SANKYO COMPANY LIMITED (JP) | 1986-02-19 | — | — | EP | disclosed |
| EP-0165384-A1 | Carbapenem derivatives, their preparation and compositions containing them | SANKYO COMPANY LIMITED (JP) | 1985-12-27 | — | — | EP | disclosed |
| US-4552873-A | BACTERICIDES | SANKYO COMPANY LIMITED (JP) | 1985-11-12 | — | — | US | disclosed |
| EP-0108942-A2 | Cephalosporin derivatives, methods of production thereof and prophylactic and therapeutic agents for bacterial infection | Kyoto Pharmaceutical Industries, Ltd. (JP) | 1984-05-23 | — | — | EP | disclosed |
| EP-0072710-A1 | Carbapenem derivatives, their preparation and compositions containing them | SANKYO COMPANY LIMITED (JP) | 1983-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | STT3B, STT3A, TTL | NAAA 507/4885HCAR2 1623/4885EPHX1 1851/4885 |
| US-20230012681-A1 | ANTIBODY DRUG CONJUGATES COMPRISING ECTEINASCIDIN DERIVATIVES | HDGF, XPOT, TXLNA | NAAA 663/4885HCAR2 3093/4885EPHX1 824/4885 |
| US-20230218774-A1 | DRUG ANTIBODY CONJUGATES | B3GAT3, MGAT3, SDAD1 | NAAA 1828/4885HCAR2 3414/4885EPHX1 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.